Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I–IIIA operable breast cancer (tumor size ≥ 1.5 cm) were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP ± endocrine therapy (group B).
The management of hereditary breast cancer has undergone a profound shift in recent years. BRCA testing is no longer simply a tool for estimating familial risk; it now informs key clinical decisions from the moment of diagnosis.
Clara García González [1] ; Vega Iranzo González-Cruz [1] [1] Hospital General Universitario de Valencia Localización: Revisiones en cáncer, ISSN 0213-8573, Vol. 37, Nº. 2, 2023, págs. 57-68 Idioma: español Enlaces Texto completo Resumen español Uno de los grandes avances acontecidos en los últimos años dentro del cáncer de mama luminal metastásico lo protagoniza la llegada de los inhibidores de cinasa dependientes de ciclina.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
